Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ALCO HEALTH SERVICES OPTING FOR $31 A SHARE LEVERAGED BUYOUT

Executive Summary

ALCO HEALTH SERVICES OPTING FOR $31 A SHARE LEVERAGED BUYOUT in the wake of the drug wholesaler's aborted $30 a share merger with McKesson. The roughly $523 mil. cash tender offer was initiated on Nov. 18. Alco Health Services parent Alco Standard will tender its 36% interest in the drug wholesaling operation in connection with the agreement. The stage was set on Nov. 11, when Alco Health disclosed that it had "received late yesterday bids for the acquisition of the company." Alco Health noted that it had formed a special committee of the board to evaluate the proposals. The company acknowledged that the bids "had been solicited by the company." The acquisition vehicle is AHSC Holdings, a newly formed entity consisting of Citicorp Capital Investors, Alco Health management and other institutional investors. Alco Health president John McNamara is heading the management group. The $31 a share bid is almost $100 mil. higher than the $26-a-share offer proposed at the beginning of last summer by a management group led by then-chairman John Kennedy. McKesson's $30 a share proposal, advanced in June, was blocked by the Federal Trade Commission in October ("The Pink Sheet' Oct. 10, p. 5). There are approximately 16.86 mil. shares of Alco Health Services stock outstanding. "Shares not purchased in the offer will be converted pursuant to the merger into the right to receive subordinated debentures of AHSC Holdings expected to have a market value on a fully distributed basis of $31," the release states. "If less than 92% of the shares are tendered, the cash not expended in the offer will be paid pro rata to shareholders in the merger and the amount of debentures for each share in the merger will be reduced by the amount of cash received." The deal is conditioned upon the tender of a majority of Alco Health Services shares. The release notes that Citicorp Capital Investors has committed to provide AHSC Holdings up to $50 mil. in subordinated debt and equity financing in connection with the offer. "Drexel Burnham Lambert has delivered a letter to AHSC Holdings stating that it is highly confident that it can raise the remainder of the financing," the release adds. Drexel also will participate as an equity partner. Alco Health Services was spun off by parent Alco Standard in August 1985.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS014625

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel